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ABSTRACT
Background: Elevated serum cardiac troponin T
(cTnT) and I (cTnI) can occur in patients with chronic
kidney disease. Differences in cTn concentrations
between cTnT and cTnI have been reported but the
mechanism of such discrepancy has not been
investigated. This study investigates the clearance of
cTn with the aid of an in vitro model of haemodialysis
(HD).
Methods: Serum was obtained before and after a
single session of dialysis from 53 patients receiving
HD and assayed for cTnT and cTnI. An in vitro model
of the dialysis process was used to investigate the
mechanism of clearance of cTn during HD.
Results: Serum cTnI was significantly lower
(p=0.043) following a session of HD whereas
cTnT concentrations were similar to those obtained
before HD.
Using an in vitro model of dialysis, it was
demonstrated that cTnI is not dialysed from the
vascular compartment but adheres to the dialyser
membrane.
Conclusions: The adherence of cTnI to the dialyser
membrane is responsible for the observed decrease in
serum cTnI following a session of dialysis. The
adherence of cTnT or T-I-C complex to the dialyser
membrane could not be demonstrated and supports
the observation that pre-HD and post-HD serum
concentrations of cTnT are similar.
INTRODUCTION
The cardiac troponins (cTn) T (cTnT) and I
(cTnI) are the gold standard tests for the
diagnosis1 and risk stratiﬁcation2 of acute
myocardial infarction (AMI). Elevated cTn
can occur in other conditions including
patients with chronic kidney disease (CKD).
The diagnosis of AMI in patients with CKD,
especially those receiving dialysis, is problem-
atic. The atypical presentations and severity
of the CKD itself often masks the classical
signs and symptoms of AMI. As the cardiac
biomarkers are cleared via the kidney, the
interpretation of such biomarkers including
cTn in those with renal impairment is a great
clinical challenge. Patients with CKD have a
reduced lifespan compared with patients
without renal disease and cardiovascular
mortality accounts for the majority of renal
deaths.3 Cardiovascular morbidity is also
increased with 55% of patients receiving
haemodialysis (HD) renal replacement
therapy demonstrating concomitant congest-
ive heart failure.4
In 1995, it was reported that serum cTnT
was elevated in patients with renal failure in
the absence of elevated cTnI5 and this was
considered to be a false positive. The reason
for this is twofold. First, the assay suffered
interference due to adsorption of skeletal
TnT (sTnT) to the assay tube wall. This
adsorbed sTnT was subsequently detected by
the non-speciﬁc signal antibody.6 This phe-
nomenon was abolished by redesigning the
assay with two cardiospeciﬁc antibodies for
capture and detection.7 This assay demon-
strated fewer cTnT elevations in patients with
CKD (5/40, 13%); however, persistent
KEY MESSAGES
▸ Serum cTnI decreases following a session of
haemodialysis.
▸ Serum cTnT does not decrease following a
session of dialysis.
▸ Cardiac troponin I adheres to polysulphone dia-
lyser membrane.
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elevations were observed in some patients with CKD sug-
gesting it is not simply a false-positive result. Second,
negative cTnI were assigned based on inappropriately
high upper reference limits for the diagnosis of AMI.
This artiﬁcially raised the diagnostic efﬁciency of cTnI.8
The use of more appropriate cut-offs demonstrated that
cTnT and cTnI were detectable in patients with renal
disease.9 The use of recently introduced high sensitivity
assays in CKD gives rise to comparable rates of detection
of cTnT and cTnI in patients with renal dysfunction.10
Prognostic studies and meta-analysis data conﬁrm that
elevated cTn in patients with CKD is of prognostic
value.11–22
There have been a number of published papers inves-
tigating changes in cTnT16 23–27 and cTnI16 25–28 in
samples taken before and after a dialysis session;
however, there is a lack of consensus in the results.
In the present study, pre-HD and post-HD serum
samples from patients undergoing HD were assayed for
cTnT and cTnI and the mechanism of clearance of cTn
was investigated using an in vitro model of HD.
METHODS
Pre-HD and post-HD serum samples
Renal patients attending the HD were invited to partici-
pate and informed consent was obtained. Whole blood
was obtained before (pre-HD) and immediately post-HD
therapy in Vacutainer serum separator gel (SST) tubes
(Becton-Dickinson, Oxford, UK). Following clotting,
centrifugation at 3000 rpm for 10 min and routine bio-
chemical analysis for clinical patient management,
residual serum samples were aliquoted and stored at
−70°C until further analysis of cTn.
Immunohistochemical staining of cellulose acetate
membranes
The experimental design occurred in two phases. In
phase 1, passive diffusion of cTn from a commercial
source in cut dialyser membranes was examined. This
was followed by phase 2, in which the counter-current
ﬂow of dialyser ﬂuid and ﬂuid in the blood compart-
ment was used to replicate the process of dialysis to dem-
onstrate the location of cTnI binding to the cuprophan
membrane. Capillary middle-ﬂux polysulfone Helixone,
FX80 (Fresenius Medical Care, Nottinghamshire, UK)
HD membranes were used throughout.
Phase 1: passive diffusion in dialyser membrane
A sterile cuprophan dialyser was ﬂushed with reagent
grade distilled water. The plastic casing was cut with a
hacksaw to remove the inlet and outlet caps.
Twenty-millimetre long sections of membrane tubing
were cut using a scalpel and the bundle was loosely
placed in a 0.5 mL Eppendorf tube. Each bundle was
washed twice with 0.1 M phosphate buffered saline
(PBS), pH 7.2. The membrane sections were then incu-
bated overnight in 1000 μL of serum spiked with free
cTnT, free cTnI and cTn I-T-C complex (HyTest Ltd,
Finland). The concentrations were 78 000 and
29 150 μg/L for free cTnI and cTnT, respectively. For the
human cTn complex, the cTnT and cTnI concentrations
were 27 420 and 30 370 μg/L, respectively.
A 1:100 concentration of M7 anti-cTnT MAb (Roche
Diagnostics, Tutzing, Germany) was incubated in one
Eppendorf tube, the other was incubated with a 1:100
dilution of 19C7 anti-cTnI MAb (HyTest Ltd, Finland) for
1 h. The membranes were rinsed three times with 0.1 M
PBS, pH 7.2, to remove any excess unbound primary anti-
body. The membranes were then incubated with biotin-
labelled mouse anti-IgG (1:1000) for a further hour,
washing unbound secondary antibody again with PBS.
The membranes were then incubated with the ﬂuores-
cent marker streptavidin-labelled ﬂuorescein isothiocyan-
ate (FITC). Membranes were transferred to cork tissue
boards and orientated either longitudinally (LS) or trans-
versely (TS). The entire block was covered in
cryo-embedding media (OCT, Tissue-Tek, Lamb Ltd, East
Sussex, UK) and snap frozen by submerging in liquid
nitrogen. The frozen tissue board was transferred to a
cryotome cryostat (−70°C) and allowed to equilibrate to
environmental temperature for 3 min prior to sectioning.
LS and TS sections, 5 μm thick, were cut and mounted
on aminoalkylsilane-coated (Silane-Prep, Sigma
Diagnostics) slides. The slides were allowed to air dry
before being visualised using ﬂuorescent microscopy
(Olympus BX-40-FLA, Olympus Optical Ltd, London,
UK) and video images were captured using Image
Grabber PCI V.2.05, (Neotech Ltd, London, UK) for
Microsoft Windows.
Phase 2: replication of counter-current flow of dialysis
In order to ascertain if cTnI crosses the dialyser mem-
brane during the dialysis process or if it remains within
the vascular compartment of the dialyser, dialysis mem-
branes were examined after simulating the process of
dialysis. Dialysate ﬂuid and a volume of serum spiked
with cTn (representing the blood compartment) were
passed through the cuprophan membrane in counter-
current ﬂow, similar to that of dialysis. A water-driven
vacuum pump was attached via the dialysate outlet and
the tubing cannulated for efﬂuent dialysate sample col-
lection. The inlet was connected to a 5 L reservoir con-
taining dialysate ﬂuid (ﬁgure 1). Renalyte acid
concentrate bicarbonate dialysate ﬂuid (Fresenius
Medical Care, Nottinghamshire, UK) was reconstituted 1
to 1.26 to 32.78 in 8.4% sodium hydrogen carbonate
and reagent grade water, respectively, as per the recom-
mended protocol of the manufacturers. The ﬁnal solu-
tion had the following composition: Na+ 103 mmol/L,
K+ 2 mmol/L, Ca++ 1.25 mmol/L, Mg++ 0.5 mmol/L, Cl−
108.5 mmol/L, CH3COO
− 3 mmol/L and glucose
5.6 mmol/L. An aliquot of the renalyte dialysate ﬂuid
working solution was tested for possible interference in
the cTnT and cTnI assays. The counter-current ﬂow rate
of dialysis ﬂuid (Qd) was controlled at 200 mL/min.
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The membranes were primed with 200 mL dialysate and
an efﬂuent sample was collected for cTnT and cTnI
assay testing before introduction of the blood
component.
Five serum pools of 50 mL volumes were constructed
from healthy volunteers free from a history of AMI and
who did not demonstrate serum cTn positivity. The
serum pools were ﬁltered and further centrifuged at
3000 rpm for 10 min to remove any particulate matter.
The pools were prepared as follows: pool A: troponin
free serum pool (no spiking); pool B: unbound free
cTnI; pool C: unbound free cTnT; pool D: troponin I-C;
pool E: troponin T-I-C complex.
For each pool constructed, a fresh sterile membrane
ﬁlter was used in the simulation. The serum pools were
injected into the blood compartment of the HD mem-
brane using a 20 mL syringe. Two-millilitre aliquots were
drawn from the blood compartment outlet repeated at
2 min intervals. In addition, 2 mL aliquot fractions of
efferent dialysate were also collected at 2 min intervals
for a period of 15 min. Samples from the blood com-
partment outlet and the efferent dialysate were assayed
for cTnT and cTnI.
Following simulated HD procedures, all membranes
were disconnected and the outer plastic shell was cut
using a hacksaw at the collar of the housing to remove
the inlet and outlet caps. Two to 4 cm long bundles of
ﬁbres were cut from the mid-section of the dialyser with
a sterile scalpel and placed into 0.5 mL Eppendorf tubes
and incubated with anti-cTn antibodies and visualised
with ﬂuorescent microscopy as described above.
cTnT assay
cTnT was determined using the fourth generation
Troponin T STAT assay on an Elecsys 2010 (Roche
Diagnostics, Haywards Heath, UK). The assay total impre-
cision was 5.4–9.3% in the range 0.47–11.5 μg/L. The
measuring range was 0.01–25 μg/L. The 10% CV was at
0.03 μg/L with a 99th centile of <0.01 μg/L.
cTnI assay
cTnI was determined using the TnI-Ultra assay for the
ADVIA Centaur (Siemens Healthcare Diagnostics,
Frimley, UK). The detection limit of the instrument was
0.006 μg/L, upper limit 50 μg/L. The manufacturers
claim was 10% CV at 0.03 μg/L with a 99th centile of
0.04 μg/L.
Data handling and statistics
All data were exported to Microsoft Excel (Microsoft
Corporation). All statistical analyses will be performed
using the Analyse-it, add-in software for Excel. Data were
examined for normal distribution. Box and whisker
plots were constructed to demonstrate the distribution
of pre-HD and post-HD cTnT and cTnI concentrations
and formally tested for statistical signiﬁcance with non-
parametric Wilcoxon signed-ranks testing. A p≤0.05 was
deemed signiﬁcant. All biomarker concentrations were
measured in triplicate and are reported as mean±SD.
RESULTS
Serum concentrations of cTn before and after dialysis
The mean pre-HD cTnT serum concentration was
0.06 μg/L which increased to 0.08 μg/L post-HD, however
this was not statistically signiﬁcant (p=0.821, ﬁgure 2A).
The mean pre-HD cTnI concentration was 0.197 μg/L
which was signiﬁcantly higher than the post-HD concen-
tration of 0.163 μg/L (p=0.043, ﬁgure 2B).
Phase 1: passive diffusion in dialyser membrane
Using cut cellulose membranes and simple passive diffu-
sion following incubation of the polysulfone membrane
in an Eppendorf tube with very high concentrations of
serum containing cTnT, cTnI and T-I-C tertiary
complex, immunoﬂuorescent signal can be seen within
the lumen in the TS (ﬁgure 3A) and LS sections of the
membrane (ﬁgure 3B) incubated with free cTnI. There
Figure 1 In vitro setup of simulated haemodialysis.
(A) Blood compartment inlet; (B) blood compartment outlet;
(C) dialysate outlet; (D) dialysate inlet; (E) dialysate reservoir;
(F) water-driven vacuum pump; (G) efferent dialysate
collection syringe.
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was a lack of immunoﬂuorescent signal when membrane
was incubated with either free cTnT (ﬁgure 3C) or T-I-C
binary complex (ﬁgure 3D). Autoﬂuorescence of the
ﬂeece ﬁbre packing material occurs (ﬁgure 3C marked
with*) which adsorbs the streptavidin-labelled FITC and
is an artefact.
Phase 2: replication of counter-current flow of dialysis
Samples of renalyte dialysate ﬂuid were below the detec-
tion limit for cTnT (<0.01 μg/L) and cTnI (<0.02 μg/L)
indicating no interference with the antibodies in the
immunoassay. Fifty millilitres of spiked serum
representing the blood (vascular compartment) which
does not come in contact with the dialysate ﬂuid was
introduced into the dialyser. The dialysate ﬂuid was
pumped counter-currently at a ﬂow rate of 200 mL/min,
typical of the dialysis procedure.
After dismantling the dialyser membrane and expos-
ure of the cellulose acetate core, it can be demonstrated
that cTn-free serum does not produce any ﬂuorescent
signal (ﬁgure 4A1). To demonstrate that the TS sections
of membrane had adequately adhered to the
Silane-Prep slide, the corresponding light micrograph is
shown in ﬁgure 4A2.
Figure 2 Box and whisker plot
demonstrating the concentrations
if (A) cardiac troponin T (cTnT)
and (B) cTnI in serum obtained
immediately prehaemodialysis
(pre-HD) and post-HD.
Figure 3 Immunofluorescence of polysulfone dialysis membranes. (A) Transverse section of membrane tube incubated with
free cardiac troponin I (cTnI) and stained with anti-cTnI MAb. (B) Longitudinal section of membrane tube incubated with free cTnI
and stained with anti-cTnI MAb. (C) Transverse section of multiple tubes incubated with free cTnT and stained with anti-cTnI M7
MAb. (D) Transverse section of a single polysulfone tube incubated with Tn T-I-C binary complex incubated with anti-cTnI and
anti-cTnT MAb (×100 magnification).
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However, when serum spiked with cTnI was circulated
through the dialysis simulation, it can be observed that a
strong ﬂuorescent signal was obtained. This signal repre-
sents cTnI from the vascular compartment which
adheres to the exterior of the cellulose acetate tubes
(ﬁgure 4B1). These data suggest that the cTnI from the
patient’s circulation has remained within the vascular
compartment of the dialysis system rather than passing
across the membrane to the dialysate.
Further evidence to support this hypothesis is that an
aliquot of the efferent dialysate ﬂuid was obtained at the
end of the experiment and assayed again for cTnI. The
dialysate ﬂuid had an undetectable cTnI concentration.
Similar analysis revealed an undetectable concentration
of cTnT in the efferent dialysate.
When samples of cTnT spiked serum (ﬁgure 4C1), I-C
binary complex spiked serum (ﬁgure 4D1) or T-I-C
tertiary complex spiked serum (ﬁgure 4E1) were circu-
lated through the dialysis simulation, there was no evi-
dence of ﬂuorescent signal, thus suggesting that all of
these cTn entities remain within the vascular compart-
ment and in the clinical scenario are reintroduced into
the patients circulation during the dialysis session.
DISCUSSION
cTnT and cTnI are the gold standard diagnostic tests for
the detection and management of acute cardiac
disease29 and are central components of the third uni-
versal deﬁnition of myocardial infarction.1
Contemporary and high-sensitivity assays demonstrate
comparative clinical sensitivity and speciﬁcity for diagno-
sis of AMI.30 31 Elevation of cTnT and cTnI occurs






standard bright field light
microscopy images. (A) Troponin
(Tn) free serum pool; (B) free
cardiac Tn I (cTnI) spiked pool;
(C) free cTnT spiked pool; (D) I-C
binary complex spiked pool; (E)
T-I-C complex spiked pool (all
images are transverse sections at
×40 magnification).
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There have been a number of published papers inves-
tigating changes in cTn concentration following an
episode of dialysis but there is a lack of consensus. Some
authors claim there are no signiﬁcant differences in pre-
dialysis and postdialysis cTn concentrations while others
refute this. Non-signiﬁcant increase in cTnT has been
demonstrated in post-HD samples23 24 whereas others
have found no change in concentrations16 25 or
decreases in cTnT.26 27 For cTnI either no change in
concentrations16 25 or decreases in concentration is
observed.26–28 Many of the early studies (pre-2005) uti-
lised high cut-off concentrations to deﬁne cTn positivity,
equivalent to the WHO derived cut point for AMI. This
results in a reduction in the number of positive samples
in CKD and the observation of non-signiﬁcant changes
or no change between pre-HD and post-HD cTn con-
centrations. In the present study, a signiﬁcant reduction
in serum cTnI post-HD was observed; however, cTnT
concentrations were similar to those before the initiation
of dialysis.
When adopting lower clinical cut-off values equivalent
to either 10% total assay coefﬁcient of variation or the
upper 99th centile of a healthy reference population,
signiﬁcant changes are often seen with cTnT increasing
and cTnI decreasing following HD treatment. It should
also be noted that Lippi et al27 further classiﬁed patients
according to type of dialyser used. Pre-HD and post-HD
cTnT and cTnI were determined from a single dialysis
session from 18 patients using low-ﬂux and 16 patients
using high-ﬂux haemodialysers. High-ﬂux membranes
cleared cTnT and cTnI more efﬁciently than low-ﬂux
membranes.
Solute removal in dialysis occurs through a combin-
ation of three processes: diffusion, convection and
adsorption. Adsorption is the adhesion of proteins and
macromolecules to the surface of the membrane
without penetration. Adsorption depends on the
internal pore structure and membrane hydrophobicity.32
Presently, it is not known how cTnI is removed during
dialysis. In this proof of concept study, dialyser mem-
branes were isolated and incubated with serum contain-
ing cTnT and cTnI. Following incubation and
immunoﬂuorescent antibody detection it was demon-
strated that cTnI is detectable on the membrane
whereas cTnT is not and suggests a reason for the dis-
parity between pre-cTnI and post-cTnI serum concentra-
tions observed in this study and by others.26–28 33 The
proof of concept study could not demonstrate if cTnI is
dialysed out of the serum during HD as the dialyser
membrane tubes were submerged in the serum during
the incubation period.
By replicating the counter-current model of HD, the
results of the proof of concept study were conﬁrmed.
There was no evidence of cTnT adhering to the polysul-
fone cellulose acetate dialyser membrane. It was;
however, possible to demonstrate that cTnI is not
cleared by the dialysis process from the circulation to
the dialysate, but is adsorbed to the membrane in the
vascular compartment. This probably occurs due to the
high theoretical isoelectric point (pI) of cTnI (9.87).
The pI is the pH at which a molecule carries no net
electrical charge. A high pI gives the cTnI molecule a
high positive charge34 making the molecule ‘sticky’ and
able to interact freely by adsorbing to the polysulfone
membrane. One limitation to the present study is the
lack of positive control as demonstrated by other pro-
teins with similar pI values. It has been demonstrated
that protein adsorption occurs at much lower isoelectric
points. Tomisawa and Yamashita35 demonstrated adsorp-
tion of albumin (pI=4.4) to polymethylmethacrylate
membranes. Mares and colleagues eluted adsorbed pro-
teins from polysulfone dialysis membranes, observing 84
proteins eluted from ﬁve dialysed patients. Of these, 57
were identiﬁed by mass spectrometry and included
ﬁcolin-2 (pI 6.1), clusterin (pI 3.7), complement frag-
ment C3c (pI=6.29) and apolipoprotein A1 (pI=5.56). A
further limitation is the ubiquitous use of a single dialy-
ser membrane surface from a single manufacturer.
Tomisawa and Yamashita35 demonstrated approximately
20% higher fractional adsorption of albumin using poly-
methylmethacrylate membranes compared with polyes-
ter polymer alloy membranes. Given that many different
membranes are used clinically, the adsorption of cTnI to
these surfaces may differ and affect post-cTnI serum
concentrations.
CONCLUSION
Using immunoﬂuorescent microscopy, it has been pos-
sible to demonstrate that cTnI is not dialysed from the
vascular compartment like other waste products but
remains within the vascular compartment and adheres
to the polysulfone cellulose acetate membrane. These
novel data provide for the ﬁrst time, a mechanism by
which cTnI decreases following dialysis while cTnT
remains similar to predialysis concentrations.
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